ARCHIVES

Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

December 27, 2013

NCI To Proceed With Guidelines Unless Board Strongly Disagree

May 9, 1980

In Surgery vs Radiotherapy, Outcome Differences Equalize After 15 Years Follow-up

February 22, 2013

NCI Awards $10 Million To States for Cervix Screening

September 27, 1974

Pitot Named New NCAB Chairman

May 4, 1979

In the States: Michigan to Allocate $50 Million Annually To Life Sciences

July 23, 1999